CHAMPION SIGNED
Cartilage Healing Approach Merging Polymer InnOvation with Nature
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0CHAMPION project word cloud
Explore the words cloud of the CHAMPION project. It provides you a very rough idea of what is the project "CHAMPION" about.
Project "CHAMPION" data sheet
The following table provides information about the project.
| Coordinator |
REGENTIS BIOMATERIALS LTD
Organization address contact info |
| Coordinator Country | Israel [IL] |
| Total cost | 3˙121˙700 € |
| EC max contribution | 2˙185˙190 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-06-01 to 2021-05-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | REGENTIS BIOMATERIALS LTD | IL (OR AKIVA) | coordinator | 2˙185˙190.00 |
Map
Project objective
Cartilage injury afflicts over one million patients annually in Europe. Focal knee cartilage defects are as painful and limiting as osteoarthritis and can lead further degradation requiring total knee replacement surgery. Focal knee cartilage injuries are typically treated by bone marrow stimulation (Microfracture) which has limited benefit due to a high failure rate, poor longterm outcome and frequent required re-interventions. Alternative therapeutic products in the form of cellular/biologicals treatments have failed due to complexity and multiple surgery risks. With the promise of cell-based procedures not realized, the pursuit of an optimal treatment for symptomatic articular cartilage defects in the knee joint remains elusive. GelrinC is a simple, off-the-shelf treatment for focal injuries in the knee cartilage. It is a ready-to-use liquid cured in-situ by ultraviolet light to form a resorbable implant conforming to the shape and depth of the defect. Unlike other acellular implants, GelrinC was designed to support the formation of hyaline cartilage through a unique Mode-of-Action: Formation of a cell barrier thus preventing migration of undesired cells into the defect. At the same time, GelrinC harnesses the established prochondrogenic potential of polyethylene glycol, its major component, to provide the right microenvironment for the body’s own stem cells to differentiate into chondrocytes. Due to the presence of the denatured human fibrinogen in GelrinC, the implant resorbs from the outside inwards and thus is gradually replaced with new hyaline-like cartilage in a synchronized process. GelrinC gained a CE mark in 2017 and it is regulatory ready for commercialization in Europe. The next steps allowing quick, successful market entrance are optimizing the production process, completing a phase III clinical trials,improving the procedure towards arthroscopic implantation; and creating commercialization channels including centres of excellence in Europe.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CHAMPION" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CHAMPION" are provided by the European Opendata Portal: CORDIS opendata.